NVS vs. TEVA: Novartis vs. Teva Pharmaceutical Stock Comparison

Company Profile

Novartis (NVS) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Both Novartis (NVS) and Teva Pharmaceutical (TEVA) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Novartis (NVS) at 24.33% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Novartis (NVS) at 17.49% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.

Both Novartis (NVS) at 34.27% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Novartis (NVS) at 9.57% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Novartis (NVS) reports EPS growth of 21.81%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Novartis (NVS) at 0.88 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Novartis (NVS) at 1.29 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novartis (NVS) at 31.02 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Novartis (NVS) at 5.35 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Teva Pharmaceutical (TEVA) at 6.23 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics